- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Drug discovery
Analysts: Lilly setbacks might spur shopping spree
October 22, 2010
Bloomberg NewsCEO John Lechleiter claims Eli Lilly and Co. isn't interested in big acquisitions to bolster its flagging drug pipeline, but
its recently devalued partner Amylin Pharmaceuticals might be the right fit, industry analysts say.
MoreLilly suspends clinical trials after diabetes treatment fails
October 20, 2010
Bloomberg NewsEli Lilly and Co. and its development partner said an experimental diabetes treatment failed to help patients in a late-stage
study, the second setback for a Lilly diabetes drug candidate in two days.
MoreUPDATE: Lilly, others see stock slide after drug rejection
October 20, 2010
Bloomberg NewsStock in Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. dropped after they were rebuffed a second time in
a bid to gain U.S. approval of a once-weekly version of the diabetes drug Byetta.
MoreFDA demands more tests on new Lilly diabetes drug
October 19, 2010
J.K. WallEli Lilly and Co. will have to wait at least 18 months and conduct more studies before it wins market approval of a once-weekly
version of diabetes drug Byetta, a potential billion-dollar drug.
MoreLilly to close drug discovery center in Singapore
October 18, 2010
Bloomberg NewsIndianapolis-based Eli Lilly and Co. will close its drug discovery center in Singapore, three years into a five-year, $150
million plan to expand it.
MoreConsultants: Pharma industry facing huge changes
October 6, 2010
J.K. Wall
To date, most analysts say health reform turned out pretty well for
the pharmaceutical industry. But a detailed analysis by Deloitte Consulting says the indirect effects of reform will deliver
a gut punch to the industry that will lead to full-scale transformation akin to what the telecommunications world has seen
over the past three decades.
CEO says Lilly still not interested in huge acquisitions
September 7, 2010
IBJ Staff and Bloomberg NewsLilly remains disinterested in making big acquisitions and aims to rely on the company’s own pipeline, CEO John Lechleiter
said Tuesday, re-emphasizing a strategy he has outlined several times in the past year.
MoreLilly wins ban of generic Strattera pending appeal
August 31, 2010
Bloomberg NewsThe U.S. Court of Appeals for the Federal Circuit in Washington on Tuesday granted Lilly's request to prevent sales until
the court rules on a judge's decision invalidating a patent on the medicine.
MoreEndocyte's $86M IPO plan a boon for Indiana, investors
August 28, 2010
Greg AndrewsVenture capitalists in Indiana and nationally have thrown money at the company with abandon. Local investors include CID Capital,
Clarian Health Ventures and the Indiana Future Fund.
MoreLilly wins further delay in sales of Strattera copies
August 26, 2010
Bloomberg NewsStrattera generated U.S. sales of $445.6 million last year, and each day that Lilly can fend off generic competition would
translate into an average $1.22 million in sales.
MoreDiabetes research pioneer Kirtley dies at 96
August 25, 2010
Associated PressDiabetics who control their disease with pills instead of frequent insulin injections can thank Dr. William R. Kirtley, a
groundbreaking Eli Lilly researcher.
MorePearl IRB first firm in state to pre-screen clinical drug trials
August 21, 2010
Chris O'MalleyTwo former Eli Lilly and Co. employees launched the firm that promises to attract more clinical trial business to the state.
MoreLilly gains panel's backing to expand Cymbalta use
August 19, 2010
Bloomberg NewsOutside advisers to the Food and Drug Administration voted 8-6 Thursday in favor of a broader use of Cymbalta on the basis
of studies in lower back pain and osteoarthritis of the knee.
MoreCancer drug developer Endocyte files for IPO
August 18, 2010
Scott OlsonThe company, headquartered at Purdue Research Park, said the number of shares to be offered and their price range have yet
to be determined.
MoreLilly Alzheimer's drug prospect only the latest to fail
August 18, 2010
Bloomberg NewsA dozen potential products designed to slow or stop clumps of protein from forming in the brain, a condition linked to the
disease since 1906, have failed in mid- to late-stage testing since 2003.
MoreLilly among bidders for Denmark company, source says
July 30, 2010
Bloomberg NewsCopenhagen-based health-care company Ascendis Pharma A/S received offers of about $400 million, an unidentified source said.
Ascendis may choose a final bidder by early September.
MoreNew rules raise stakes for Lilly drug
July 21, 2010
J.K. WallDrugmakers testing experimental Alzheimer’s medicines—including Eli Lilly and Co.—got good news last week
when the National Institute on Aging and the Alzheimer’s Association proposed new guidelines to make earlier diagnoses
of the disease.
MoreLilly's Alzheimer's gamble takes aim at $10 billion in patent losses
July 13, 2010
Bloomberg NewsBoth of Lilly's late-stage treatments are designed to reduce plaque in the brain called beta amyloid, thought by researchers
to be a main contributor to Alzheimer's. A drug that stops or reduces memory loss caused by Alzheimer's may be worth more
than $5 billion
a year, an analyst says, helping Lilly overcome the coming patent losses on several important pharmaceuticals.
MoreDiagnostics division to help Lilly tailor treatments
July 10, 2010
J.K. WallEli Lilly and Co. is launching a diagnostics division to produce tests that can winnow out the patients most likely to benefit
from a Lilly drug.
MoreMarcadia enlists Lilly to help develop new diabetes drug
June 28, 2010
J.K. WallThe two companies will jointly develop a short-acting glucagon drug, which they hope proves more convenient than Lilly’s
current Glucagon for patients with severe hypoglycemia.
MoreLilly, Amylin stock rises on drug postponement
June 18, 2010
IBJ Staff and Bloomberg NewsRoche Holding AG's decision to postpone its experimental diabetes drug is helping boost shares in Amylin Pharmaceuticals
Inc. and drug partner Eli Lilly and Co.
MoreCancer researcher battling Semafore in court
May 29, 2010
Chris O'MalleyFormer collaborator alleges firm breached its agreement with him and refused to pay royalty income.
MoreBiopharma fueling boom in refrigerated warehousing
May 29, 2010
Chris O'MalleyIn the past few years, a handful of cold storage facilities have sprouted locally by playing to Indianapolis' strengths
in warehousing and life sciences.
MoreLilly hopes Elanco unit becomes a cash cow
May 8, 2010
J.K. WallElanco Animal Health chief Jeff Simmons predicts that consumers will opt for food made cheaper by using
Elanco's productivity-enhancing drugs over pricier organic and locally grown products. But, as a hedge,
he has Elanco developing products to help organic farmers, too.
MoreChao exit hurts drug development industry
April 28, 2010
J.K. WallPurdue University’s decision to close the Chao Center in West Lafayette is a setback for Indiana’s effort to grow
a vibrant contract drug manufacturing sector. But it’s just the latest in a series of unexpected changes—not all
for
the worse—since Indianapolis-based BioCrossroads launched a contract drug manufacturing initiative in late 2007.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
"And the success of the Indiana GOP to not allow an expansion of Medicaid had nothing to do with Indiana hospitals' financial woes? Fixed that for you; editorial bias rebalanced. Seriously, there are so many things wrong with Obamacare that the only way one can view it as a success is to assume that it was designed to fail our way into a government single payor healthcare system. The system is complex, creates huge regulatory burdens and overhead and yet still does not have adequate means to control escalating health care costs. But then when you elect a 10th grade math drop out with no quantitative reasoning skills to be President of one of the world's most important economies in troubled times, you can't really be surprised by blatant stupidity.
No NIMBYs here to chase off a decent development. We don't need tons of parking and we'd happily play the role of host to a downtown Whole Foods.
Whatever you do, don't change a single thing about Broad Ripple. I want it to look just like it did in the late '70s, with 30% of the north side of Broad Ripple Avenue burned out and plenty of places to park. That's right Broad Ripple, NEVER CHANGE. Let the world pass you by, don't improve your empty, abandoned lots full of weeds. Someday someone will want to film a zombie movie here.
Hollywood could step in and make a movie about the history about this forlorn series. It could be a full celebrity cast of characters. WOW. http://www.advanceindiana.blogspot.com/2013/02/indiana-taxpayers-forced-to-pay-for.html
This shouldn't come as a shock to many. Austin is a great city, and Indy needs to take some notes. Austin invests in decent transit options, has a highly educated workforce, embraces a creative class, and --despite being the state capital-- is not micromanaged by rural and suburban legislators. Want Indy to grow? Invest in the city (i.e. spend money). Raise taxes a bit, and use the money to improve education. And keep the state legislature out of Indy the other 9 months of the year.